These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 36828479)
1. Role of Urological Botulinum Toxin-A Injection for Overactive Bladder and Voiding Dysfunction in Patients with Parkinson's Disease or Post-Stroke. Hu JC; Hsu LN; Lee WC; Chuang YC; Wang HJ Toxins (Basel); 2023 Feb; 15(2):. PubMed ID: 36828479 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison. Cruz F; Danchenko N; Fahrbach K; Freitag A; Tarpey J; Whalen J J Med Econ; 2023; 26(1):200-207. PubMed ID: 36647624 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease. Vurture G; Peyronnet B; Feigin A; Biagioni MC; Gilbert R; Rosenblum N; Frucht S; Di Rocco A; Nitti VW; Brucker BM Neurourol Urodyn; 2018 Nov; 37(8):2669-2677. PubMed ID: 29767449 [TBL] [Abstract][Full Text] [Related]
4. Intradetrusor onabotulinum-a toxin injections in children with therapy-resistant idiopathic detrusor overactivity. A retrospective study. Ringoir A; Dhondt B; De Bleser E; Van Laecke E; Everaert K; Groen LA; Hoebeke P; Spinoit AF J Pediatr Urol; 2020 Apr; 16(2):181.e1-181.e8. PubMed ID: 31964616 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders. Lin YH; Chiang BJ; Liao CH Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085522 [TBL] [Abstract][Full Text] [Related]
6. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019 [TBL] [Abstract][Full Text] [Related]
7. [Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease]. Atamian A; Sichez PC; Michel F; Bandelier Q; Fall M; Gaillet S; Azoulay JP; Lechevallier E; Karsenty G Prog Urol; 2021 Jun; 31(7):430-438. PubMed ID: 33579624 [TBL] [Abstract][Full Text] [Related]
8. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Karsenty G; Baverstock R; Carlson K; Diaz DC; Cruz F; Dmochowski R; Fulford S; Giannantoni A; Heesakkers J; Kaufmann A; Peyrat L; Thavaseelan J; Dasgupta P Int J Clin Pract; 2014 Jun; 68(6):731-42. PubMed ID: 24472109 [TBL] [Abstract][Full Text] [Related]
9. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO). Nambiar A; Lucas M Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139 [TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity. Conte A; Giannantoni A; Proietti S; Giovannozzi S; Fabbrini G; Rossi A; Porena M; Berardelli A Eur J Neurol; 2012 May; 19(5):725-32. PubMed ID: 22212295 [TBL] [Abstract][Full Text] [Related]
12. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. Linsenmeyer TA J Spinal Cord Med; 2013 Sep; 36(5):402-19. PubMed ID: 23941788 [TBL] [Abstract][Full Text] [Related]
13. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Kalsi V; Apostolidis A; Popat R; Gonzales G; Fowler CJ; Dasgupta P Eur Urol; 2006 Mar; 49(3):528-35. PubMed ID: 16426735 [TBL] [Abstract][Full Text] [Related]
15. Use of botulinum toxin for genitourinary conditions: What is the evidence? da Silva CM; Chancellor MB; Smith CP; Cruz F Toxicon; 2015 Dec; 107(Pt A):141-7. PubMed ID: 26235907 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population. Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R; Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394 [TBL] [Abstract][Full Text] [Related]
17. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB). Cruz F; Nitti V Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140 [TBL] [Abstract][Full Text] [Related]
19. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446 [TBL] [Abstract][Full Text] [Related]
20. [Pittsburgh experience with botulinum toxin A injection]. de Miguel F; Chancellor MB Actas Urol Esp; 2006 Mar; 30(3):310-4. PubMed ID: 16749589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]